Although senior leadership has been re-organized, the actual consistency and interactivity of the team remains stable. In fact, Dr. DiPaola was appointed as Director of CINJ following multiple appointments at CINJ including Co-Leader of the Prostate Program, Chief of Medical Oncology and Associate Director for Clinical Science. Dr. Edmund Lattime, a prior Associate Director, was appointed to the position of Deputy Director in 2008 by Dr. DiPaola. Dr. Joseph R. Bertino remains as Chief Scientific Officer. Dr. Michael Reiss continues as Associate Director for Translational Science and has appropriately assumed oversight of all basic science and translational shared resources. Dr. Eileen White, a Program Leader since 2004, was appointed Associate Director for Basic Science and, following a move of her laboratories to the main CINJ building in New Brunswick, increased basic science mentorship at CINJ. Dr. Joseph Aisner is Associate Director for Clinical Science as in the 2004 review, and Dr. Susan Goodin has been appointed Assistant Director for Clinical Science and Director ofthe Office of Human Research Services. Stability in administration also remains, as Ms. Linda Barker continues as Associate Director for Administration and Planning. As a new leader. Dr. Helmut Zarbl was appointed Associate Director for Public Health Science, overseeing CINJ's efforts in prevention, control, and population science. Salary support for these individuals is requested only for the effort attributable to research-related activities

Public Health Relevance

The senior leadership supports the mission ofthe Cancer Institute of New Jersey (CINJ) as a National Cancer institute (NCI)-designated comprehensive cancer center to increase scientific depth and breadth in basic, clinical and public health sciences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA072720-16W3
Application #
8728111
Study Section
Subcommittee G - Education (NCI)
Project Start
2013-07-01
Project End
2017-02-28
Budget Start
2013-07-01
Budget End
2014-02-28
Support Year
16
Fiscal Year
2013
Total Cost
$49,999
Indirect Cost
$18,553
Name
University of Medicine & Dentistry of NJ
Department
Type
DUNS #
617022384
City
Piscataway
State
NJ
Country
United States
Zip Code
08854
Modi, Parth K; Wang, Ye; Kirk, Peter S et al. (2018) The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology 117:50-56
Dai, Zhuqing; Feng, Simin; Liu, Anna et al. (2018) Anti-inflammatory effects of newly synthesized ?-galacto-oligosaccharides on dextran sulfate sodium-induced colitis in C57BL/6J mice. Food Res Int 109:350-357
Farber, Nicholas J; Faiena, Izak; Dombrovskiy, Viktor et al. (2018) Disparities in the Use of Continent Urinary Diversions after Radical Cystectomy for Bladder Cancer. Bladder Cancer 4:113-120
Lee, Jongin; Lee, Daehwan; Sim, Mikang et al. (2018) mySyntenyPortal: an application package to construct websites for synteny block analysis. BMC Bioinformatics 19:216
DeRenzo, Evan G; Moss, Joel; Singer, Eric A (2018) Implications of the Revised Common Rule for Human Participant Research. Chest :
Feng, Simin; Dai, Zhuqing; Liu, Anna B et al. (2018) Intake of stigmasterol and ?-sitosterol alters lipid metabolism and alleviates NAFLD in mice fed a high-fat western-style diet. Biochim Biophys Acta Mol Cell Biol Lipids 1863:1274-1284
Song, Mihae; Kumaran, Muthu N; Gounder, Murugesan et al. (2018) Phase I trial of selenium plus chemotherapy in gynecologic cancers. Gynecol Oncol 150:478-486
Khiabanian, Hossein; Hirshfield, Kim M; Goldfinger, Mendel et al. (2018) Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data. JCO Precis Oncol 2018:
Rabadan, Raul; Bhanot, Gyan; Marsilio, Sonia et al. (2018) On statistical modeling of sequencing noise in high depth data to assess tumor evolution. J Stat Phys 172:143-155
Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated whole breast irradiation is cost-effective-but is that enough to change practice? Transl Cancer Res 7:S469-S472

Showing the most recent 10 out of 775 publications